University Hospital of Rouen
Rouen, 76031, France
NCT Number: NCT07026812
Short stature is defined as a height less than -2 Standard Deviations (SD) for age and a slowing of growth velocity by a loss of 1 SD/year. The causes of short stature are multiple (chronic diseases, growth hormone deficiency, hypothyroidism, hyperadrenocorticism, genetic syndromes, etc.). However, nearly 30% are considered idiopathic, with no identified etiology (Naccache et al., unpublished).
Growth hormone (GH) is secreted in a pulsatile manner with maximum peaks primarily at night, raising questions about the relationship between sleep disturbances and short stature.
In children, one of the main causes of sleep disturbances in the digital age is screen use, which is becoming increasingly important, particularly in the pediatric population.
Looking for future studies?
Notify Me6 year–16 year
All sexes
Observational
Rouen, 76031, France
During the night, physiologically, the retina, which no longer receives light signals, sends a message to the suprachiasmatic nucleus, the main key element of the internal clock, and to the pineal gland, which synthesizes melatonin, the sleep hormone. Exposing screens to blue light therefore disrupts melatonin secretion, which leads to a disruption of the circadian rhythm and therefore sleep. Note that this effect of light on melatonin secretion depends on the time of day of exposure, the intensity, and the duration. Thus, exposure to screens before bedtime can be responsible for a delay or even an absence of melatonin synthesis, particularly in the case of nighttime awakenings.
While many studies have examined the impact of screens on children's psychological balance, weight, etc., none, to our knowledge, has examined the potential impact of screens on children's height growth. Hypothesis of this project: 70% of GH synthesis takes place at night, a few minutes after entering slow-wave sleep, sleep disturbed by screens could mean a lower secretion of GH and consequently a delay in height growth.
The objective of this project is to evaluate the impact of screen consumption on sleep and the impact of sleep on idiopathic growth disorder.
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Time frame: At enrollment visit
Evaluation of the Impact of Screen Consumption on Sleep by Answers to the Questionnaire Given to the Child and/or Parent(s) (Depending on Age)
Time frame: At enrollment visit
Sleep assessment by responses to the questionnaire given to the child and/or the parent(s) (depending on age) in order to assess the duration of sleep
Time frame: At enrollment visit
Evaluation of the Impact of Screen Consumption on Sleep by Answers to the Questionnaire Given to the Child and/or Parent(s) (Depending on Age) in Order to Evaluate child's physical activity
Time frame: At enrollment visit
Collection of auxological data at the time of the day hospital consultation (height) noted in the health record and/or in the hospital medical file
Time frame: At enrollment visit
Collection of auxological data at the time of the day hospital consultation (weight) noted in the health record and/or in the hospital medical file
Time frame: At enrollment visit
Collection of auxological data at the time of the day hospital consultation (age) noted in the health record and/or in the hospital medical file
Time frame: At enrollment visit
Evaluation of the impact of screens on body size (BMI) by response to the questionnaire given to the child and/or the parent(s)
University Hospital, Rouen
Other
Acronym: ECROIPED
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT05033119
Antipsychotics and Neuroleptics Toxicity, Brain Diseases
Aalborg, Denmark
View Trial DetailsNCT05934422
Allergy, Atopic Dermatitis
Auckland, New Zealand
View Trial DetailsNCT05419336
Child Development, Growth Disorders
London, United Kingdom
View Trial DetailsNCT05829252
Bone Diseases, Bone Diseases, Developmental
London, United Kingdom
View Trial Details